UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

310 Inhibition of Trk-driven tumors by the pan-Trk inhibitor RXDX-101

European journal of cancer (1990), 2014-11, Vol.50, p.101-101

2014

Volltextzugriff (PDF)

Anti‐tumour efficacy on glioma models of PHA‐848125, a multi‐kinase inhibitor able to cross the blood–brain barrier

British journal of pharmacology, 2013-05, Vol.169 (1), p.156-166

2013

Volltextzugriff (PDF)

NMS-P088, a CSF-1R, FLT3 and KIT inhibitor with outstanding activity on gatekeeper resistance mutations, high tolerability, and potential for combination therapies

European journal of cancer (1990), 2016-12, Vol.69, p.S127-S128

2016

Volltextzugriff (PDF)

31 N-Myc amplification sensitizes tumor cells to inhibition by Danusertib, an Aurora kinase inhibitor

European journal of cancer (1990), 2014-11, Vol.50, p.16-16

2014

Volltextzugriff (PDF)

544 Characterization of Potent and Well Tolerated Second Generation FLT3 Inhibitors

European journal of cancer (1990), 2012-11, Vol.48, p.167-167

2012

Volltextzugriff (PDF)

The Basic Domain in HIV-1 Tat Protein as a Target for Polysulfonated Heparin-mimicking Extracellular Tat Antagonists

The Journal of biological chemistry, 1998-06, Vol.273 (26), p.16027-16037

1998

Volltextzugriff (PDF)

3-Aminopyrazole Inhibitors of CDK2/Cyclin A as Antitumor Agents. 1. Lead Finding

Journal of medicinal chemistry, 2004-06, Vol.47 (13), p.3367-3380

2004

Volltextzugriff (PDF)

3-Aminopyrazole Inhibitors of CDK2/Cyclin A as Antitumor Agents. 2. Lead Optimization

Journal of medicinal chemistry, 2005-04, Vol.48 (8), p.2944-2956

2005

Volltextzugriff (PDF)

388 - NMS-P088, a CSF-1R, FLT3 and KIT inhibitor with outstanding activity on gatekeeper resistance mutations, high tolerability, and potential for combination therapies

European journal of cancer (1990), 2016-12, Vol.69, p.S127-S128

2016

Volltextzugriff (PDF)

Analysis of Brostallicin Effect on Different Human Gastrointestinal Cancer Cell Lines

Letters in drug design & discovery, 2006-10, Vol.3 (8), p.524-527

2006

Volltextzugriff (PDF)

Optimization of Diarylthiazole B-Raf Inhibitors: Identification of a Compound Endowed with High Oral Antitumor Activity, Mitigated hERG Inhibition, and Low Paradoxical Effect

ChemMedChem, 2015-02, Vol.10 (2), p.276-295

2015

Volltextzugriff (PDF)

3-Amino-1,4,5,6-tetrahydropyrrolo[3,4- c]pyrazoles: A new class of CDK2 inhibitors

Bioorganic & medicinal chemistry letters, 2006-02, Vol.16 (4), p.1084-1090

2006

Volltextzugriff (PDF)

Antitumor Efficacy of Edotecarin as a Single Agent and in Combination with Chemotherapy Agents in a Xenograft Model

Clinical cancer research, 2006-05, Vol.12 (9), p.2856-2861

2006

Volltextzugriff (PDF)

Effects of topoisomerase II inhibitors on gastric cancer cells characterized by different genetic lesions

Anticancer research, 2001-07, Vol.21 (4A), p.2803

2001

Volltextzugriff (PDF)

Decreased tyrosine phosphorylation in tumour cells resistant to FCE 24517 (tallimustine)

British journal of cancer, 1995-12, Vol.72 (6), p.1504-1508

1995

Volltextzugriff (PDF)

Multiple effects of paclitaxel are modulated by a high c- myc amplification level

Experimental cell research, 2003-10, Vol.290 (1), p.49-59

2003

Volltextzugriff (PDF)

Phase I/II trial of nemorubicin hydrochloride in combination with cisplatin is supported by new preclinical evidences of its mechanism of action

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.14116-14116

2006

Volltextzugriff (PDF)

Bombesin stimulates growth of human prostatic cancer cells in vitro

Cancer, 1989-05, Vol.63 (9), p.1714-1720

1989

Volltextzugriff (PDF)

In vitro and in vivo activity of alkylating bombesin receptor antagonists on small cell lung carcinoma

Anticancer research, 1993-01, Vol.13 (1), p.75

1993

Volltextzugriff (PDF)

FCE 27266, a sulfonic distamycin derivative, inhibits experimental and spontaneous lung and liver metastasis

Invasion and metastasis, 1995, Vol.15 (5-6), p.222

1995

Volltextzugriff (PDF)

3-Aminopyrazole Inhibitors of CDK2/Cyclin A as Antitumor Agents. 2. Lead Optimization

Journal of medicinal chemistry, 2005-07, Vol.48 (15), p.5058-5058

2005

Volltextzugriff (PDF)

Pharmacological and toxicological aspects of 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548) : A novel antineoplastic agent

Cancer research (Chicago, Ill.), 2001-03, Vol.61 (5), p.1983-1990

2001

Volltextzugriff (PDF)

304 POSTER Combination treatment of new molecular-targeted therapies and the DNA minor groove binder brostallicin

European journal of cancer supplements, 2006-11, Vol.4 (12), p.95-96

2006

Volltextzugriff (PDF)

New sulfonated distamycin a derivatives with bFGF complexing activity

Biochemical pharmacology, 1994-01, Vol.47 (2), p.295-302

1994

Volltextzugriff (PDF)

Synthesis and binding mode of heterocyclic analogues of suramin inhibiting the human basic fibroblast growth factor

Bioorganic & medicinal chemistry, 1998-07, Vol.6 (7), p.947-958

1998

Volltextzugriff (PDF)

1 – 25 von 54

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(48)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(53)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(33)
Life Sciences & Biomedicine
(31)
Animals
(21)
Humans
(21)
Mice
(19)
Biological And Medical Sciences
(16)
Pharmacology & Pharmacy
(16)
Medical Sciences
(13)
Pharmacology. Drug Treatments
(13)
Antineoplastic Agents
(12)
Antineoplastic Agents - Pharmacology
(12)
Tumor Cells, Cultured
(10)
Cell Division - Drug Effects
(9)
Chemistry, Medicinal
(9)
Oncology
(9)
Drug Screening Assays, Antitumor
(8)
Distamycins - Pharmacology
(7)
Mice, Inbred Balb C
(7)
Mice, Nude
(7)
Structure-Activity Relationship
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

310 Inhibition of Trk-driven tumors by the pan-Trk inhibitor RXDX-101

Anti‐tumour efficacy on glioma models of PHA‐848125, a multi‐kinase inhibitor able to cross the blood–brain barrier

NMS-P088, a CSF-1R, FLT3 and KIT inhibitor with outstanding activity on gatekeeper resistance mutations, high tolerability, and potential for combination therapies

31 N-Myc amplification sensitizes tumor cells to inhibition by Danusertib, an Aurora kinase inhibitor

544 Characterization of Potent and Well Tolerated Second Generation FLT3 Inhibitors

The Basic Domain in HIV-1 Tat Protein as a Target for Polysulfonated Heparin-mimicking Extracellular Tat Antagonists

3-Aminopyrazole Inhibitors of CDK2/Cyclin A as Antitumor Agents. 1. Lead Finding

3-Aminopyrazole Inhibitors of CDK2/Cyclin A as Antitumor Agents. 2. Lead Optimization

388 - NMS-P088, a CSF-1R, FLT3 and KIT inhibitor with outstanding activity on gatekeeper resistance mutations, high tolerability, and potential for combination therapies

Analysis of Brostallicin Effect on Different Human Gastrointestinal Cancer Cell Lines

Optimization of Diarylthiazole B-Raf Inhibitors: Identification of a Compound Endowed with High Oral Antitumor Activity, Mitigated hERG Inhibition, and Low Paradoxical Effect

3-Amino-1,4,5,6-tetrahydropyrrolo[3,4- c]pyrazoles: A new class of CDK2 inhibitors

Antitumor Efficacy of Edotecarin as a Single Agent and in Combination with Chemotherapy Agents in a Xenograft Model

Effects of topoisomerase II inhibitors on gastric cancer cells characterized by different genetic lesions

Decreased tyrosine phosphorylation in tumour cells resistant to FCE 24517 (tallimustine)

Multiple effects of paclitaxel are modulated by a high c- myc amplification level

Phase I/II trial of nemorubicin hydrochloride in combination with cisplatin is supported by new preclinical evidences of its mechanism of action

Bombesin stimulates growth of human prostatic cancer cells in vitro

In vitro and in vivo activity of alkylating bombesin receptor antagonists on small cell lung carcinoma

FCE 27266, a sulfonic distamycin derivative, inhibits experimental and spontaneous lung and liver metastasis

3-Aminopyrazole Inhibitors of CDK2/Cyclin A as Antitumor Agents. 2. Lead Optimization

Pharmacological and toxicological aspects of 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548) : A novel antineoplastic agent

304 POSTER Combination treatment of new molecular-targeted therapies and the DNA minor groove binder brostallicin

New sulfonated distamycin a derivatives with bFGF complexing activity

Synthesis and binding mode of heterocyclic analogues of suramin inhibiting the human basic fibroblast growth factor

Suchergebnisse filtern